SB590885

SB590885 is a potent and selective small molecule inhibitor of B-Raf kinase, specifically categorized as a Type 1 RAF inhibitor that binds to the active conformation of the kinase. Originally developed by GSK, the compound is widely utilized in preclinical oncology research to investigate the MAPK/ERK signaling pathway. It has demonstrated significant activity in inhibiting ERK phosphorylation and inducing apoptosis in BRAF-mutant melanoma and RAS-mutant acute myeloid leukemia (AML) models. While primarily used as a research tool to study resistance mechanisms and synergistic drug combinations, SB590885 serves as a foundational molecule for understanding the structural biology of RAF inhibition.